190 related articles for article (PubMed ID: 32706277)
1. Egyptian experience in Langerhans cells histiocytosis: frequent multisystem affection and reactivation rates.
Tantawy AAG; Ragab IA; Elsherif NHK; Makkeyah SM; AbdelRaheem HG; Elsantiel HIE
Pediatr Hematol Oncol; 2020 Nov; 37(8):696-706. PubMed ID: 32706277
[No Abstract] [Full Text] [Related]
2. Treatment of Langerhans cell histiocytosis with a modified risk-adapted protocol-experience from a tertiary cancer institute in India.
Narula G; Pradhan ND; Arora B; Banavali SD
Pediatr Blood Cancer; 2018 Aug; 65(8):e27028. PubMed ID: 29512864
[TBL] [Abstract][Full Text] [Related]
3. [Clinical manifestations of Langerhans cell histiocytosis with multisystem involvement in 53 children].
Tang JJ; Xu XJ; Wang YC; Bai ST; Wang L; Ni XL; Liu YF
Zhonghua Er Ke Za Zhi; 2021 Jan; 59(1):37-41. PubMed ID: 33397002
[No Abstract] [Full Text] [Related]
4. Langerhans Cell Histiocytosis (LCH) in Egyptian Children: Does Reactivation Affect the Outcome?
Sedky MS; Rahman HA; Moussa E; Taha H; Raafat T; Hassanein O
Indian J Pediatr; 2016 Mar; 83(3):214-9. PubMed ID: 26133729
[TBL] [Abstract][Full Text] [Related]
5. Outcome of High-risk Langerhans Cell Histiocytosis (LCH) in Egyptian Children, Does Intermediate-dose Methotrexate Improve the Outcome?
Sedky MS; Hamouda A; Taha H; Zaky I; Hassanain O; El Hemaly A; ElHaddad A
J Pediatr Hematol Oncol; 2019 Nov; 41(8):635-643. PubMed ID: 30247183
[TBL] [Abstract][Full Text] [Related]
6. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis.
Gadner H; Minkov M; Grois N; Pötschger U; Thiem E; Aricò M; Astigarraga I; Braier J; Donadieu J; Henter JI; Janka-Schaub G; McClain KL; Weitzman S; Windebank K; Ladisch S;
Blood; 2013 Jun; 121(25):5006-14. PubMed ID: 23589673
[TBL] [Abstract][Full Text] [Related]
7. Clinical and prognostic characteristics of 95 cases of Langerhans cell histiocytosis in children: a single-institute experience from 2013 to 2020.
Tang X; Gao J; Ma ZG; Guo X; Li Q; Wan Z; Sun JJ
Ann Med; 2021 Dec; 53(1):1537-1546. PubMed ID: 34459688
[TBL] [Abstract][Full Text] [Related]
8. Intensified and prolonged therapy comprising cytarabine, vincristine and prednisolone improves outcome in patients with multisystem Langerhans cell histiocytosis: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study.
Morimoto A; Shioda Y; Imamura T; Kudo K; Kawaguchi H; Sakashita K; Yasui M; Koga Y; Kobayashi R; Ishii E; Fujimoto J; Horibe K; Bessho F; Tsunematsu Y; Imashuku S
Int J Hematol; 2016 Jul; 104(1):99-109. PubMed ID: 27040279
[TBL] [Abstract][Full Text] [Related]
9. Reactivations in multisystem Langerhans cell histiocytosis: data of the international LCH registry.
Minkov M; Steiner M; Pötschger U; Aricò M; Braier J; Donadieu J; Grois N; Henter JI; Janka G; McClain K; Weitzman S; Windebank K; Ladisch S; Gadner H;
J Pediatr; 2008 Nov; 153(5):700-5, 705.e1-2. PubMed ID: 18589441
[TBL] [Abstract][Full Text] [Related]
10. Multisystem Langerhans cell histiocytosis in children: current treatment and future directions.
Minkov M
Paediatr Drugs; 2011 Apr; 13(2):75-86. PubMed ID: 21351807
[TBL] [Abstract][Full Text] [Related]
11. Long-term follow-up of children with risk organ-negative Langerhans cell histiocytosis after 2-chlorodeoxyadenosine treatment.
Barkaoui MA; Queheille E; Aladjidi N; Plat G; Jeziorski E; Moshous D; Lambilliotte A; Kebaili K; Pacquement H; Leverger G; Mansuy L; Entz-Werlé N; Bodet D; Schneider P; Pagnier A; Lutun A; Gillibert-Yvert M; Millot F; Toutain F; Reguerre Y; Thomas C; Tazi A; Emile JF; Donadieu J; Héritier S
Br J Haematol; 2020 Dec; 191(5):825-834. PubMed ID: 32700439
[TBL] [Abstract][Full Text] [Related]
12. Clinical features and treatment outcomes of pediatric Langerhans cell histiocytosis with macrophage activation syndrome-hemophagocytic lymphohistiocytosis.
Wang D; Chen XH; Wei A; Zhou CJ; Zhang X; Ma HH; Lian HY; Zhang L; Zhang Q; Huang XT; Wang CJ; Yang Y; Liu W; Wang TY; Li ZG; Cui L; Zhang R
Orphanet J Rare Dis; 2022 Apr; 17(1):151. PubMed ID: 35379272
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of children younger than 24 months with langerhans cell histiocytosis and bone involvement: a report from a single institution.
Kamath S; Arkader A; Jubran RF
J Pediatr Orthop; 2014 Dec; 34(8):825-30. PubMed ID: 25387157
[TBL] [Abstract][Full Text] [Related]
14. Vinblastine chemotherapy in adult patients with langerhans cell histiocytosis: a multicenter retrospective study.
Tazi A; Lorillon G; Haroche J; Neel A; Dominique S; Aouba A; Bouaziz JD; de Margerie-Melon C; Bugnet E; Cottin V; Comont T; Lavigne C; Kahn JE; Donadieu J; Chevret S
Orphanet J Rare Dis; 2017 May; 12(1):95. PubMed ID: 28532436
[TBL] [Abstract][Full Text] [Related]
15. Treatment of multisystem Langerhans cell histiocytosis. Results of the DAL-HX 83 and DAL-HX 90 studies. DAL-HX Study Group.
Minkov M; Grois N; Heitger A; Pötschger U; Westermeier T; Gadner H
Klin Padiatr; 2000; 212(4):139-44. PubMed ID: 10994540
[TBL] [Abstract][Full Text] [Related]
16. Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: results of an international phase 2 study.
Donadieu J; Bernard F; van Noesel M; Barkaoui M; Bardet O; Mura R; Arico M; Piguet C; Gandemer V; Armari Alla C; Clausen N; Jeziorski E; Lambilliote A; Weitzman S; Henter JI; Van Den Bos C;
Blood; 2015 Sep; 126(12):1415-23. PubMed ID: 26194764
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes and prognostic risk factors of Langerhans cell histiocytosis in children: Results from the BCH-LCH 2014 protocol study.
Cui L; Wang CJ; Lian HY; Zhang L; Ma HH; Wang D; Chen FF; Zhang Q; Yang Y; Wei A; Huang XT; Zhu T; Wang TY; Li ZG; Zhang R
Am J Hematol; 2023 Apr; 98(4):598-607. PubMed ID: 36594188
[TBL] [Abstract][Full Text] [Related]
18. [Clinical study of 131 children with multi-system Langerhans cell histiocytosis].
Wu FF; Gao YJ; Pan C; Chen J; Tang JY
Zhonghua Er Ke Za Zhi; 2016 May; 54(5):349-53. PubMed ID: 27143076
[TBL] [Abstract][Full Text] [Related]
19. A multicenter study of patients with multisystem Langerhans cell histiocytosis who develop secondary hemophagocytic lymphohistiocytosis.
Chellapandian D; Hines MR; Zhang R; Jeng M; van den Bos C; Santa-María López V; Lehmberg K; Sieni E; Wang Y; Nakano T; Williams JA; Fustino NJ; Astigarraga I; Dunkel IJ; Abla O; van Halteren AGS; Pei D; Cheng C; Weitzman S; Sung L; Nichols KE
Cancer; 2019 Mar; 125(6):963-971. PubMed ID: 30521100
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of children with multiple system Langerhans cell histiocytosis by Japan Langerhans Cell Histiocytosis Study Group Protocol].
Huang JB; Xue HM; Chen YY; Huang K
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Feb; 21(1):146-9. PubMed ID: 23484709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
